menu
    • menu
    [{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"177-Lu DOTA-EB-TATE","moa":"SST2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Targeting Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Molecular Targeting Technologies \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Molecular Targeting Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"ClinSmart","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"177-Lu DOTA-EB-TATE","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Targeting Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Molecular Targeting Technologies \/ ClinSmart","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Targeting Technologies \/ ClinSmart"},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"177-Lu DOTA-EB-TATE","moa":"SST2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"Molecular Targeting Technologies","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Molecular Targeting Technologies \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Molecular Targeting Technologies \/ Undisclosed"},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"National Institute for Biomedical Imaging and Bioengineering","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"177-Lu DOTA-EB-TATE","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Targeting Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Molecular Targeting Technologies \/ National Institute for Biomedical Imaging and Bioengineering","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Targeting Technologies \/ National Institute for Biomedical Imaging and Bioengineering"},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"177-Lu EBTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Molecular Targeting Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Targeting Technologies \/ Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Targeting Technologies \/ Eczac\u0131ba\u015f\u0131-Monrol Nuclear Products"},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"Molecular Targeting Technologies","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"BELGIUM","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"99m-Tc Duramycin","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Molecular Targeting Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Targeting Technologies \/ Molecular Targeting Technologies","highestDevelopmentStatusID":"6","companyTruncated":"Molecular Targeting Technologies \/ Molecular Targeting Technologies"},{"orgOrder":0,"company":"Molecular Targeting Technologies","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"99mTc-Duramycin","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Molecular Targeting Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Molecular Targeting Technologies \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Molecular Targeting Technologies \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Molecular Targeting Technologies

    Menu

    Molecular Targeting Technologies

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Molecular Targeting Technologies

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Molecular Targeting Technologies

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu DOTA-EB-TATE

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Molecular Targeting Technologies, Inc. and Molecular Theranostics Center of Singapore Receive HSA Approval for...

                            Details : EBTATE (177Lu-DOTA-EB-TATE) is the first patented and only long-acting peptide receptor radionuclide therapy (PRRT) targeting SSTR2 receptors, which is being investigated for the treatment of nasopharyngeal cancer.

                            Product Name : Ebtate

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 02, 2023

                            Lead Product(s) : 177-Lu DOTA-EB-TATE

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Molecular Targeting Technologies

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Molecular Targeting Technologies

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu DOTA-EB-TATE

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MTTI Obtains FDA Allowance of Investigational New Drug (IND) for Hürthle Cell Thyroid Cancer

                            Details : EBTATE (177Lu-DOTA-EB-TATE) is a new generation of peptide receptor radiotherapeutic drug that has demonstrated potential clinical superiority over standard of care. It selectively binds to somatostatin receptor 2 (SSTR2) on neuroendocrine and other tumo...

                            Product Name : Ebtate

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            December 08, 2022

                            Lead Product(s) : 177-Lu DOTA-EB-TATE

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Molecular Targeting Technologies

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Molecular Targeting Technologies

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu DOTA-EB-TATE

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : ClinSmart

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors

                            Details : 177-Lu DOTA-EB-TATE is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neuroendocrine Tumors.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 26, 2022

                            Lead Product(s) : 177-Lu DOTA-EB-TATE

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : ClinSmart

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Molecular Targeting Technologies

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Molecular Targeting Technologies

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu DOTA-EB-TATE

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : National Institute for Biomedical Imaging and Bioengineering

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MTTI Doses First Patient in EBTATE Neuroendocrine Tumor Clinical Trial

                            Details : EBTATE (177Lu-DOTA-EB-TATE) is a patented peptide targeting radiotherapeutic drug. It selectively targets and binds to somatostatin receptor 2 on neuroendocrine tumors, which are then killed by the radionuclide.

                            Product Name : Ebtate

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 29, 2022

                            Lead Product(s) : 177-Lu DOTA-EB-TATE

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : National Institute for Biomedical Imaging and Bioengineering

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Molecular Targeting Technologies

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Molecular Targeting Technologies

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 99m-Tc Duramycin

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Recipient : University Hospital Antwerp

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biodistribution and Dosimetry of 99mTc-Duramycin

                            Details : 99m-Tc Duramycin is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            January 04, 2022

                            Lead Product(s) : 99m-Tc Duramycin

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Recipient : University Hospital Antwerp

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Molecular Targeting Technologies

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Molecular Targeting Technologies

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177-Lu EBTATE

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Eczacıbaşı-Monrol Nuclear Products

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            MTTI and Monrol Have Signed a Clinical Supply Agreement for Lu-177 n.c.a.

                            Details : A timely and sustainable supply of a key therapeutic ingredient (n.c.a.177Lu) needed for the development and launch of company lead asset 177Lu-EBTATE and other EB platform technologies.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            November 24, 2021

                            Lead Product(s) : 177-Lu EBTATE

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Eczacıbaşı-Monrol Nuclear Products

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Molecular Targeting Technologies

                            U.S.A arrow
                            CPhI India
                            Not Confirmed

                            Molecular Targeting Technologies

                            U.S.A arrow
                            CPhI India
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 99mTc-Duramycin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Molecular Targeting Technologies and University of Antwerp Begin Study of TDURA Diagnostic to Detect Response ...

                            Details : Study will evaluate the safety, dosimetry and treatment response of TDURA (99mTc-Duramycin) for advanced colorectal cancer. Duramycin, a naturally occurring peptide that binds to phosphatidylethanolamine, has been radiolabeled and used for early imaging ...

                            Product Name : TDURA

                            Product Type : Radiolabeled Compound

                            Upfront Cash : Inapplicable

                            May 11, 2021

                            Lead Product(s) : 99mTc-Duramycin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth